JP2011525388A - 緑内障の併用治療 - Google Patents

緑内障の併用治療 Download PDF

Info

Publication number
JP2011525388A
JP2011525388A JP2011514898A JP2011514898A JP2011525388A JP 2011525388 A JP2011525388 A JP 2011525388A JP 2011514898 A JP2011514898 A JP 2011514898A JP 2011514898 A JP2011514898 A JP 2011514898A JP 2011525388 A JP2011525388 A JP 2011525388A
Authority
JP
Japan
Prior art keywords
latanoprost
delivery system
eye
days
punctal plug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011514898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011525388A5 (https=
Inventor
ブトゥーナー，ズハル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QLT Plug Delivery Inc
Original Assignee
QLT Plug Delivery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by QLT Plug Delivery Inc filed Critical QLT Plug Delivery Inc
Publication of JP2011525388A publication Critical patent/JP2011525388A/ja
Publication of JP2011525388A5 publication Critical patent/JP2011525388A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
JP2011514898A 2008-06-24 2009-06-24 緑内障の併用治療 Pending JP2011525388A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7528408P 2008-06-24 2008-06-24
US61/075,284 2008-06-24
PCT/US2009/048452 WO2010008883A1 (en) 2008-06-24 2009-06-24 Combination treatment of glaucoma

Publications (2)

Publication Number Publication Date
JP2011525388A true JP2011525388A (ja) 2011-09-22
JP2011525388A5 JP2011525388A5 (https=) 2012-08-02

Family

ID=41431875

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011514898A Pending JP2011525388A (ja) 2008-06-24 2009-06-24 緑内障の併用治療

Country Status (7)

Country Link
US (1) US20090318549A1 (https=)
EP (1) EP2303184A4 (https=)
JP (1) JP2011525388A (https=)
CN (1) CN102105118A (https=)
CA (1) CA2728623A1 (https=)
TW (1) TW201012469A (https=)
WO (1) WO2010008883A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506931A (ja) * 2013-01-24 2016-03-07 ライジェル ファーマシューティカルズ， インコーポレイテッド 点眼用組成物
WO2016047366A1 (ja) * 2014-09-22 2016-03-31 株式会社カネカ 内視鏡用注射器具
JP2021530253A (ja) * 2018-03-29 2021-11-11 マティ セラピューティクス，インク． 眼科用徐放性製剤およびドライアイ症候群治療のための使用

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1765454T3 (en) 2004-07-02 2016-05-02 Mati Therapeutics Inc Device for submission of treatment medium to eye
EP2004172B1 (en) 2006-03-31 2019-03-13 Mati Therapeutics Inc. Drug delivery structures and compositions for nasolacrimal system
NZ583858A (en) 2007-09-07 2012-08-31 Quadra Logic Tech Inc Lacrimal implant detection with detection device
CN102123713A (zh) * 2008-05-09 2011-07-13 Qlt栓塞输送公司 治疗青光眼和眼高血压的活性剂的持续释放递送
EP2437684B1 (en) 2009-06-03 2022-06-15 ForSight Vision5, Inc. Anterior segment drug delivery
US10272040B2 (en) 2010-08-12 2019-04-30 Nanyang Technological University Liposomal formulation for ocular drug delivery
US8591484B2 (en) 2010-09-15 2013-11-26 AlphaMed, Inc. Lacrimal punctum measurement and occlusion
US20120312840A1 (en) * 2011-05-13 2012-12-13 Ayako Hasegawa Container closure system with integral antimicrobial additives
ES2727203T3 (es) 2011-08-29 2019-10-14 Mati Therapeutics Inc Administración por liberación sostenida de agentes activos para tratar glaucoma e hipertensión ocular
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
EP2755615B1 (en) 2011-09-14 2022-04-06 Forsight Vision5, Inc. Ocular insert apparatus
DK2911623T3 (da) 2012-10-26 2019-10-28 Forsight Vision5 Inc Oftalmisk system til langvarig frigivelse af lægemiddel til øjet
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9424722B2 (en) * 2014-05-14 2016-08-23 Unlimited Liability, LLC Smart memory material lock devices
WO2016083891A1 (en) * 2014-11-25 2016-06-02 Eyal Sheetrit Compositions and methods for delivering a bio-active agent or bio-active agents
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US11291847B2 (en) * 2015-06-16 2022-04-05 The Regents Of The University Of Colorado, A Body Corporate Systems and methods for preventing, diagnosing, and/or treating one or more medical conditions via neuromodulation
CN105879126A (zh) * 2016-03-24 2016-08-24 杭州亚慧生物科技有限公司 一种超润滑血清白蛋白泪点塞及其制备方法
CN109568138B (zh) * 2019-01-10 2021-06-25 新疆国际旅行卫生保健中心 药片分割装置
US12447045B2 (en) 2019-10-02 2025-10-21 Segal Innovations LLC Bio-adhesive dissolving compounds and device
US11207267B2 (en) 2019-10-02 2021-12-28 Segal Innovations LLC Bio-adhesive dissolving compounds and device
US12023276B2 (en) 2021-02-24 2024-07-02 Ocular Therapeutix, Inc. Intracanalicular depot inserter device

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070269487A1 (en) * 2006-03-31 2007-11-22 Forsight Labs, Llc Drug Delivery Methods, Structures, and Compositions for Nasolacrimal System
JP2007535537A (ja) * 2004-04-30 2007-12-06 アラーガン、インコーポレイテッド プロスタミド含有生分解性眼内インプラント

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281654A (en) * 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US5589563A (en) * 1992-04-24 1996-12-31 The Polymer Technology Group Surface-modifying endgroups for biomedical polymers
CA2134087C (en) * 1992-04-24 2007-07-17 Robert S. Ward Copolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight range
US6196993B1 (en) * 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
ES2172415B2 (es) * 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
CA2513751C (en) * 2003-01-24 2012-01-10 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
EP1603485A4 (en) * 2003-02-26 2011-03-30 Medivas Llc BIOACTIVE STENTS AND METHOD OF USE THEREOF
US7662864B2 (en) * 2003-06-04 2010-02-16 Rutgers, The State University Of New Jersey Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent
US20050129731A1 (en) * 2003-11-03 2005-06-16 Roland Horres Biocompatible, biostable coating of medical surfaces
US20050232972A1 (en) * 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
WO2007047744A2 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Method for treating primary and secondary forms of glaucoma
MX2009006146A (es) * 2006-12-18 2009-06-19 Alcon Res Ltd Dispositivos y metodos para la administracion de farmacos oftalmicos.
UY30883A1 (es) * 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
AU2008300013A1 (en) * 2007-09-07 2009-03-19 Qlt Inc. Drug cores for sustained release of therapeutic agents
CN102670352A (zh) * 2007-09-07 2012-09-19 Qlt股份有限公司 用于泪腺植入物的插入和抽出工具
CA2698508C (en) * 2007-09-07 2017-06-06 Alan R. Rapacki Lacrimal implants and related methods
SG188155A1 (en) * 2008-02-18 2013-03-28 Quadra Logic Tech Inc Lacrimal implants and related methods
WO2009134371A2 (en) * 2008-04-30 2009-11-05 Qlt Plug Delivery, Inc. Composite lacrimal insert and related methods
CN102123713A (zh) * 2008-05-09 2011-07-13 Qlt栓塞输送公司 治疗青光眼和眼高血压的活性剂的持续释放递送

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007535537A (ja) * 2004-04-30 2007-12-06 アラーガン、インコーポレイテッド プロスタミド含有生分解性眼内インプラント
US20070269487A1 (en) * 2006-03-31 2007-11-22 Forsight Labs, Llc Drug Delivery Methods, Structures, and Compositions for Nasolacrimal System

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013063689; ＰＡＴＥＬ，　Ｓ．　Ｓ．　ｅｔ　ａｌ: 'ＬＡＴＡＮＯＰＲＯＳＴ　Ａ　ＲＥＶＩＥＷ　ＯＦ　ＩＴＳ　ＰＨＡＲＭＡＣＯＬＯＧＩＣＡＬ　ＰＲＯＰＥＲＩＴＥＳ，　ＣＬＩＮＩＣＡＬ　ＥＦＦＩＣＡＣＹ　ＡＮＤ　ＴＯＬＥＲＡＢＩＬＩＴＹ　ＩＮ　ＴＨＥ　ＭＡ' ＤＲＵＧＳ　＆　ＡＧＩＮＧ Ｖｏｌ．９，　Ｎｏ．５, 1996, ｐ．３６３-３７８ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506931A (ja) * 2013-01-24 2016-03-07 ライジェル ファーマシューティカルズ， インコーポレイテッド 点眼用組成物
WO2016047366A1 (ja) * 2014-09-22 2016-03-31 株式会社カネカ 内視鏡用注射器具
JPWO2016047366A1 (ja) * 2014-09-22 2017-06-29 株式会社カネカ 内視鏡用注射器具
JP2021530253A (ja) * 2018-03-29 2021-11-11 マティ セラピューティクス，インク． 眼科用徐放性製剤およびドライアイ症候群治療のための使用

Also Published As

Publication number Publication date
EP2303184A1 (en) 2011-04-06
CA2728623A1 (en) 2010-01-21
US20090318549A1 (en) 2009-12-24
EP2303184A4 (en) 2013-06-19
CN102105118A (zh) 2011-06-22
WO2010008883A1 (en) 2010-01-21
TW201012469A (en) 2010-04-01

Similar Documents

Publication Publication Date Title
JP2011525388A (ja) 緑内障の併用治療
TWI454285B (zh) 治療青光眼及高眼壓之活性劑之持續釋放輸送
US10632012B2 (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
JP5885244B2 (ja) １つまたは複数の薬剤の徐放性送達
US20100274224A1 (en) Lacrimal implant body including comforting agent
US20140025022A1 (en) Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
JP6213560B2 (ja) 薬剤送達システムならびに開放隅角緑内障および高眼圧症を治療する方法
HK1156835A (zh) 青光眼的聯合治療
HK1158951A (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
HK1162151B (en) Sustained released delivery of one or more agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140722